Related Experiment Video

Updated: Apr 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Molecular biology and targeted therapies for urothelial carcinoma

Emmanuel Seront1, Jean-Pascal Machiels2

  • 1Department of Medical Oncology, Hôpital de Jolimont, Rue Ferrer 159, 7100 La Louvière, Belgium; Institut Roi Albert II, Service d'Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.

Cancer Treatment Reviews
|April 2, 2015
PubMed

Insights

Metastatic urothelial cancer (UC) has a poor prognosis, with platinum chemotherapy resistance creating an unmet need for new treatments. This review explores bladder cancer mechanisms and promising new therapies in clinical trials.

Area of Science:

  • Oncology
  • Urothelial Carcinoma Research
  • Cancer Therapeutics

Background:

  • Metastatic urothelial cancer (UC) presents a significant clinical challenge with poor patient outcomes.
  • Platinum-based chemotherapy is the standard first-line treatment but is often met with rapid resistance.
  • There is a critical need for novel therapeutic strategies following platinum failure in UC.

Purpose of the Study:

  • To review key molecular mechanisms driving bladder cancer tumorigenesis.
  • To describe emerging therapeutic options for urothelial cancer currently in clinical trials.
  • To highlight advancements in treating metastatic urothelial cancer.

Main Methods:

  • Literature review of molecular signaling pathways in UC.
  • Analysis of current clinical trial data for novel UC agents.
  • Synthesis of information on bladder cancer pathogenesis and treatment strategies.

Main Results:

  • Understanding UC molecular pathways has spurred innovative therapeutic development.
  • Many new agents show limited efficacy as single agents; combination strategies are under investigation.
  • Promising results are emerging from ongoing clinical trials for novel UC treatments.

Conclusions:

  • New therapeutic strategies targeting UC molecular mechanisms are under active investigation.
  • Despite challenges with single-agent efficacy, ongoing research offers hope for improved outcomes.
  • This review provides an overview of current research directions in metastatic urothelial cancer treatment.
Keywords:
Bladder cancerSignaling pathwaysTargeted therapiesTreatmentTumorigenesisUrothelial carcinoma

More Related Videos

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

11.0K
An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

13.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
71
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K